BCTX · Briacell Therapeutics

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.

Bellevue Centre, West Vancouver, BC, V7T 2X1, Canada
Biotechnology
Healthcare

Market Cap

28.64M

52 Wk Range

$2.60 - $13.09

Previous Close

$3.28

Open

$3.29

Volume

63,881

Day Range

$3.15 - $3.30

Enterprise Value

7.881M

Cash

20.54M

Avg Qtr Burn

-5.959M

Insider Ownership

0.14%

Institutional Own.

5.35%

Qtr Updated

Jul 31st 2026